Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
David P. Southwell
|
| gptkbp:developedBy |
TCR-engineered T cell therapies
|
| gptkbp:focusesOn |
infectious diseases
immunotherapy T cell receptor (TCR) therapies |
| gptkbp:foundedYear |
2018
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
TScan Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:pipeline |
solid tumors
hematologic malignancies infectious disease programs |
| gptkbp:platform |
TargetScan
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
TCRX
|
| gptkbp:website |
https://www.tscan.com/
|
| gptkbp:bfsParent |
gptkb:Michael_Pellini
gptkb:Michael_J._Pellini gptkb:Stanley_Lapidus |
| gptkbp:bfsLayer |
7
|